Friday, July 10, 2026

pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)

Shire

Shire clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

JP HQ
3,523 Employees
NMPA registrant Type
Company details
Status
Public
HQ
JP
Employees
3,523
Programs
9
Drugs
8
Patents
0
Intelligence · Clinical Programs

Shire projects

4 ClinicalTrials.gov programs sponsored by Shire.

Shire has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Maribavir

    Shire

    Cytomegalovirus (CMV)

    phase 3 small molecule completed

    2 trials
  2. Ontamalimab

    Shire

    Crohn's Disease

    phase 3 small molecule terminated

    1 trial
  3. SHP615

    Shire

    Nervous System Diseases

    phase 3 small molecule completed

    1 trial
  4. velaglucerase alfa

    Shire

    Gaucher Disease

    phase 3 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Shire have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.